Tariffs, Trade, and Transformation: Decoding the US Pharma Shock for India
April 6, 2026
The Indian pharmaceutical market closed FY26 on a strong and encouraging note, signaling a shift from sluggish volume trends to a more stable and growth-oriented phase. After several quarters of muted or negative unit expansion, the sector witnessed a meaningful recovery in demand—particularly in chronic therapies—reshaping the future trajectory of the industry.
One of the most significant highlights of FY26 was the revival in volume growth. According to PharmaTrac data, the Indian Pharmaceutical Market (IPM) recorded approximately 1.7% volume growth in the March 2026 quarter, marking the strongest quarterly performance in over a year. This rebound is crucial because it reflects genuine consumption growth rather than just price-driven expansion, which had dominated previous quarters.
In terms of overall performance, the IPM registered around 10.5% year-on-year value growth in March 2026, indicating a healthy combination of pricing power, new product launches, and improving demand fundamentals. While price increases still contributed significantly, the return of positive volume growth suggests a more balanced and sustainable market environment.
Chronic Therapies Take the Lead
A defining feature of FY26 has been the dominance of chronic therapies such as cardiac, anti-diabetic, and lifestyle-related treatments. These segments have emerged as the primary growth engines of the Indian pharma market. Chronic therapies are not only growing faster but are also becoming a larger share of the overall market, accounting for more than half of total industry value.
This shift is largely driven by the rising burden of non-communicable diseases in India, including diabetes, hypertension, and cardiovascular conditions. As patients require long-term medication and better adherence, pharmaceutical companies are increasingly focusing on these high-value, recurring therapy areas. In fact, chronic therapies are expanding at nearly double the pace of acute treatments, reinforcing their strategic importance.
Weakness in Acute Segment
While the overall market showed strength, not all segments performed equally. Acute therapies such as antibiotics, painkillers, and anti-infectives continued to face weak demand. This slowdown can be attributed to factors such as seasonality, lower incidence of infections, and changing prescribing patterns.
The contrast between chronic and acute segments highlights a structural transformation in the Indian pharma landscape. The industry is gradually moving away from short-term illness treatments toward long-term disease management, which offers better margins and consistent growth opportunities.
Transition to a Value-Driven Market
Another key trend observed in FY26 is the transition toward a value-driven pharmaceutical market. Growth is increasingly supported by premium products, improved therapy adherence, and specialized treatments rather than just high volumes of low-cost medicines.
This evolution is also aligned with India’s broader healthcare transformation, where patients are becoming more aware, diagnosis rates are improving, and access to advanced therapies is expanding. Additionally, the introduction of new drug formulations and innovative therapies is contributing to incremental value creation.
Opportunities for Pharma Companies
The FY26 performance offers several strategic insights for pharmaceutical companies operating in India:
- Focus on chronic portfolios: Companies with strong offerings in cardiac, diabetes, and CNS segments are likely to outperform.
- Invest in innovation and specialty drugs: The shift toward premiumization creates opportunities for differentiated products.
- Strengthen distribution networks: Improved reach can help capture rising demand in both urban and semi-urban markets.
- Enhance patient engagement: Better adherence programs and awareness campaigns can drive long-term growth.
The Road Ahead
Looking forward, the Indian pharmaceutical market appears well-positioned for steady expansion. The recovery in volume growth, coupled with sustained demand in chronic therapies, indicates a healthier and more resilient industry outlook. However, challenges such as uneven segment performance, pricing pressures, and global uncertainties will continue to influence growth dynamics.
Overall, FY26 marks a turning point for the Indian pharma sector. With chronic therapies leading the charge and volume growth making a comeback, the industry is entering a new phase—one that emphasizes sustainability, value creation, and patient-centric innovation.
